Noida,21 August 2026: OneAlphaMed has announced a new leadership mandate with Abhishek Ghosh taking charge as Managing Director, as the company looks to accelerate its growth and expand its footprint across the pharmaceutical and healthcare communications landscape. With over 19 years of experience in pharmaceutical marketing and healthcare communications, Abhishek brings a strong track record across leading pharmaceutical organisations and healthcare ventures. He was earlier a Co-founder of MediSage, where he played a key role in building the company, which went on to raise $7 million in Series A funding from Bessemer Venture Partners in 2022.
Throughout his career, Abhishek has led marketing programmes, brand-building initiatives and product launches across India and international markets. He has worked with leading pharmaceutical organisations including Sanofi, Ranbaxy, Sun Pharma, AstraZeneca, Baxter and Sanofi Genzyme, with experience spanning pharmaceutical marketing, strategic initiatives and healthcare innovation. His notable work includes the launch of Allegra M for Sanofi in 2011 and Forxiga for AstraZeneca in 2015.
Abhishek holds a Bachelor of Pharmacy from Manipal University and an MBA in Marketing from ICFAI Business School, bringing together a strong foundation in pharmaceutical sciences with extensive experience in marketing, healthcare and business leadership.
“I’m excited to take on the role of Managing Director at OneAlphaMed and lead the company through its next phase of growth. My priority will be to strengthen our capabilities, deepen our partnerships across the pharmaceutical and life sciences industry, and deliver solutions that create measurable value. We will also expand our presence across Southeast Asia and the Middle East, bringing our trusted, innovative, and future-ready approach to a broader healthcare ecosystem,” said Abhishek Ghosh, Managing Director, OneAlphaMed.”
About OneAlphaMed:
OneAlphaMed is a pharma-specific AI and medical communications company focused exclusively on the pharmaceutical and life sciences sector. Founded in 2024, the company was created to address a gap in the healthcare ecosystem: bringing pharmaceutical strategy, medical expertise, technology and communication capabilities together under one organisation.The company works with pharmaceutical, biotech and life sciences organisations across the product lifecycle, from pre-launch and regulatory strategy through medical affairs programmes and established brands, including specialty and rare-disease portfolios. OneAlphaMed currently works with 35 large pharmaceutical companies across India and Indonesia and engages healthcare professionals, payers, HTA bodies and patients through its programmes.
